Post by Alvotech

The Goldman Sachs Global Healthcare Conference in Miami provided a timely opportunity to discuss the U.S. FDA acceptance of our Biologics License Application for our proposed interchangeable biosimilar candidate in immunology, one of our most significant regulatory submissions to date.   Róbert Wessman and Dr Balaji V Prasad also highlighted the importance of last week’s BLA resubmissions for our two biosimilar candidates in immunology and ophthalmology, reinforcing the momentum across our pipeline and our commitment to expanding patient access to high-quality biologic medicines in key therapeutic areas worldwide.   Thank you to Matt D. for hosting the conversation, and to everyone who joined the discussion. 🎧 Listen here: https://lnkd.in/eUU-if6f